Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Hanger Orthopedic

This article was originally published in The Gray Sheet

Executive Summary

Hanger Orthopedic: Announces merger agreement with privately owned, Alpharetta, Georgia-based J.E. Hanger, distributor of prosthetic and orthotic supplies and components. The deal, valued at approximately $49 mil., will create "the largest O&P practice management company with combined revenues in excess of $110 mil.," Hanger says. Under terms of the deal, Bethesda, Maryland-based Hanger will acquire all of JEH's outstanding shares in exchange for $44 mil. cash and one million Hanger shares of common stock. Finalization of the agreement is contingent upon numerous conditions including JEH's shareholder approval. Hanger is a practice management company for orthotics and prosthetics...

You may also be interested in...



Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

UK MHRA Updates Assistive Tech And Borderline Regulations

Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006465

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel